Trial Profile
BIO-SPAN: BIOsimilar switch, Study on Persistence and role of Attribution and Nocebo
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatic disorders; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BIO-SPAN
- 02 Apr 2018 According to results (6-Month) published in the Arthritis and Rheumatology Journal, the last six months evaluation was performed in May 2017.
- 02 Apr 2018 According to results (6-Month) published in the Arthritis and Rheumatology Journal, secondary endpoints for this study also included reasons for SB4 or ENB discontinuation, prediction of SB4 discontinuation and differences in disease activity measures over six months.
- 02 Apr 2018 Results (6-Month) published in the Arthritis and Rheumatology Journal.